Van Hulzen Asset Management LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 8,160 shares of the biopharmaceutical company

Dearborn Partners LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 69,875 shares of the biopharmaceutical company

Gilead Sciences received European Commission approval for Trodelvy plus Keytruda to treat PD-L1-positive metastatic triple-negative breast cancer.

OMERS ADMINISTRATION Corp bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to its most recent filing with the SEC. The fund bought 441,303 shares of the biopharmaceutical company

Meiji Yasuda Asset Management Co Ltd. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 33,417 shares of the biophar

Te Ahumairangi Investment Management Ltd purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 48,936 shares of the biopharmaceuti

Gilead Sciences stock is getting support from its latest quarter after $7.80 billion in revenue and

Sanctuary Advisors LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 203,044 shares of the biopharmaceutical company

Osmosis Investment Management UK Ltd purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 90,311 shares of the biopharmac

Cibc World Market Inc. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 338,002 shares of the biopharmaceutical company

Kiltearn Partners LLP purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 94,871 shares of the biopharmaceutical company

Northwestern Mutual Wealth Management Co. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 92,216 shares of the biopharma

Varma Mutual Pension Insurance Co acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 208,515 shares of the biopharmaceutical company

Elevation Point Wealth Partners LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 27,671 shares of the biopharmaceutica

Daiichi Life Insurance Co. Ltd. bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 183,684 shares of the biopharmaceutical company

Kendall Capital Management purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,362 shares of the biopharmaceutical company

WealthShield Partners LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 13,549 shares of the biopharmaceutical company